CMS’ Barry Straube Chats About Coverage-With-Evidence Development
This article was originally published in The Pink Sheet Daily
Straube vows that CMS' coverage-with-evidence development policy will not be used to restrict coverage for new technologies.
You may also be interested in...
Purchase of Inamed would give Allergan entry into the facial aesthetics market and augment Allergan's Botox franchise. The $3.2 bil. offer for Inamed marks a $450 mil. premium over fellow bidder Medicis.
The firm is discussing partnerships with Merck, GSK to co-promote use of its HPV test with forthcoming human papillomavirus vaccines.
Medicare Payment Advisory Commission’s June report to Congress suggests drug and device manufacturers that have completed cost-effectiveness analyses could share them with CMS. Advisory group also names possible federal agencies that might aid in conducting government-sponsored cost-effectiveness research for certain expensive medical products.